[go: up one dir, main page]

CN102771593A - Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method - Google Patents

Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method Download PDF

Info

Publication number
CN102771593A
CN102771593A CN2011101234671A CN201110123467A CN102771593A CN 102771593 A CN102771593 A CN 102771593A CN 2011101234671 A CN2011101234671 A CN 2011101234671A CN 201110123467 A CN201110123467 A CN 201110123467A CN 102771593 A CN102771593 A CN 102771593A
Authority
CN
China
Prior art keywords
preparation
vine tea
blood
extract
add
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011101234671A
Other languages
Chinese (zh)
Inventor
贾强
罗文敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou Institute of Biology
Original Assignee
Guizhou Institute of Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou Institute of Biology filed Critical Guizhou Institute of Biology
Priority to CN2011101234671A priority Critical patent/CN102771593A/en
Publication of CN102771593A publication Critical patent/CN102771593A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Belonging to the technical field of traditional Chinese medicine and health care product processing, the invention relates to an Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method. The preparation solves the problem of applying Ampelopsis grossedentata in reducing blood sugar, blood lipid and blood pressure, its effective component utilization rate is high, and the production process is simplified. The preparation method consists of: crushing Ampelopsis grossedentata tender branches and leaves, carrying out water extraction or alcohol extraction one to three times, conducting filtration, combining filtrates, adding an organic solvent for separation or directly conducting concentrating to obtain an extract, performing drying, adding auxiliary materials, mixing the materials, conducting granulation and tabletting, and implementing sugarcoating, thus obtaining tablets or capsules or soluble granules (granules) or other oral preparations.

Description

一种降血糖、血脂、血压的藤茶制剂及其制备方法A kind of rattan tea preparation for lowering blood sugar, blood fat and blood pressure and preparation method thereof

技术领域 technical field

本发明涉及一种降血糖、血脂、血压的藤茶制剂及其制备方法,具体地说涉及到藤茶有效成分的提取及其生产方法,属于中药、保健品加工技术领域。The invention relates to a rattan tea preparation for lowering blood sugar, blood fat and blood pressure and a preparation method thereof, in particular to the extraction of active ingredients of rattan tea and a production method thereof, and belongs to the technical field of traditional Chinese medicine and health care product processing.

背景技术 Background technique

藤茶,俗称茅岩莓茶、端午茶、藤婆茶(又称山甜茶、龙须茶),系葡萄科蛇葡萄属显齿蛇葡萄科(Ampelopsis grossedentata)(Hand-Mazz)W.T.wang的嫩茎叶。微苦甘长,生津止渴;其味甘甜性凉,具有清热解毒、抗菌消炎、祛风除湿、强筋骨、降血脂、保肝护肝等功效。目前现有技术对藤茶的药理实验刚刚进入初步阶段,已有对其进行降血脂、降血糖的研究报道,但尚未见对藤茶降血压的研究报道,且没有藤茶单独应用三降方面的专利,在现有的研究利用上,多为复方制剂,与其他食品、中药配置使用,未见单方使用,使用效果不理想,增加了成本和不可控的成分;要对疾病起疗效,需要较大的剂量,而且起效时间较长;本发明专利解决了藤茶单独应用在降血糖、血脂、血压三功能的问题,成本低,疗效好,克服单方藤茶利用程度低,有效成分提取率低的缺点。Vine tea, commonly known as Maoyan berry tea, Duanwu tea, and vine tea (also known as mountain sweet tea, dragon beard tea), is a tender product of Ampelopsis grossedentata (Hand-Mazz) W.T.wang. stems and leaves. Slightly bitter and sweet, it produces body fluid and quenches thirst; its taste is sweet and cool, and has the functions of clearing away heat and detoxification, antibacterial and anti-inflammatory, expelling wind and dampness, strengthening bones and muscles, lowering blood fat, and protecting liver and liver. At present, the pharmacological experiments on rattan tea in the prior art have just entered the preliminary stage, and there have been research reports on lowering blood fat and blood sugar, but there is no research report on rattan tea lowering blood pressure, and there is no single application of rattan tea in the three lowering aspects. In the existing research and utilization, most of them are compound preparations, which are used in combination with other foods and traditional Chinese medicines. There is no unilateral use, and the use effect is not ideal, which increases the cost and uncontrollable ingredients; to have a curative effect on the disease, it needs Larger dosage, and longer onset time; the patent of the invention solves the problem of the single application of vine tea in lowering blood sugar, blood fat, and blood pressure, with low cost and good curative effect, and overcomes the low utilization degree of single vine tea The disadvantage of low rate.

发明内容 Contents of the invention

针对现有的技术存在的上述缺陷,本发明旨在提供一种使用藤茶单方,提高藤茶利用程度,有效成分提取率高的提取方法及使用效果好的制剂及生产方法。Aiming at the above-mentioned defects in the existing technology, the present invention aims to provide an extraction method that uses vine tea alone, improves the utilization degree of vine tea, and has a high extraction rate of active ingredients, and a preparation and production method with good use effect.

为了实现上述目的,本发明采用以下技术方案:In order to achieve the above object, the present invention adopts the following technical solutions:

将藤茶嫩枝叶粉碎,经过水或乙醇提取,水提取液滤过,合并滤液,进一步加入有机溶剂分离纯化或不使用有机溶剂,浓缩成浸膏,加入辅料,混合,制粒,压片,包糖衣,制成片剂或胶囊或冲剂(颗粒剂)或其它口服制剂。本发明中可以加入收集藤茶挥发油,水提取采用在室温或者在加热沸腾条件下进行,水的用量为至少能没过药材,乙醇提取在室温条件下进行,提取次数至少一至三次,醇的用量为至少能没过药材,乙醇用量过多不限,乙醇采用无水乙醇或者各种浓度乙醇;加入的有机溶剂采用氯仿、乙酸乙酯、石油醚等,石油醚可以采用石油醚-30、石油醚-60或石油醚-90。Pulverize the twigs and leaves of vine tea, extract with water or ethanol, filter the water extract, combine the filtrate, add an organic solvent for separation and purification or concentrate it into an extract, add auxiliary materials, mix, granulate, and tablet, Coated with sugar, made into tablets or capsules or granules (granules) or other oral preparations. In the present invention, can be added to collect vine tea volatile oil, water extraction is carried out at room temperature or under heating and boiling conditions, the amount of water is at least able to cover the medicinal materials, ethanol extraction is carried out at room temperature, the number of extractions is at least one to three times, the amount of alcohol In order to at least cover the medicinal materials, there is no limit to the amount of ethanol. Absolute ethanol or various concentrations of ethanol are used for ethanol; chloroform, ethyl acetate, petroleum ether, etc. are used as organic solvents, and petroleum ether-30, petroleum ether, etc. can be used for petroleum ether. Ether-60 or Petroleum Ether-90.

藤茶降血脂、降血糖、降血压药效学实验,由中山大学医学院动物实验中心进行的对本发明的藤茶制剂进行动物大白鼠的降血脂、降血糖和降血压的研究,结果表明:本发明的藤茶制剂的低、中、高剂量灌胃给药对对大鼠血脂、血糖及血压与空白对照组比较,均有显著降低,在统计学上有显著差异。The rattan tea lowering blood fat, lowering blood sugar, lowering blood pressure pharmacodynamics experiment, the rattan tea preparation of the present invention is carried out the research of lowering blood fat, lowering blood sugar and lowering blood pressure of animal rats carried out by Animal Experiment Center of Sun Yat-sen University School of Medicine, the result shows: Compared with the blank control group, the low, medium and high doses of the rattan tea preparation by intragastric administration can significantly reduce the blood fat, blood sugar and blood pressure of rats, and there is a statistically significant difference.

在降血脂试验中,本发明的藤茶制剂的低、中、高剂量给药对小鼠总胆固醇(TC)、甘油三酯(TG)水平,与空白对照组比较,均有显著降低,在统计学上有显著差异。与阳性药物地奥心血康对照比较,实施例组可降低大鼠总胆固醇(TC)水平和甘油三酯(TG)水平,使大鼠血脂有显著降低,在统计学上有显著差异,具有明显的降脂效果。In the hypolipidemic test, the low, medium and high doses of the rattan tea preparation of the present invention all significantly reduce the levels of total cholesterol (TC) and triglyceride (TG) in mice compared with the blank control group. Statistically significant difference. Compared with the positive drug Di'ao Xinxuekang, the embodiment group can reduce the total cholesterol (TC) level and triglyceride (TG) level in rats, so that the blood lipids of rats are significantly reduced, and there is a statistically significant difference, which has obvious lipid-lowering effects. Effect.

本发明的藤茶制剂对实验动物小鼠的降血糖实验中,本发明的藤茶制剂的低、中、高剂量给药对小鼠血清葡萄糖水平,与空白对照组比较,均有显著降低,在统计学上有显著差异。与阳性对照药物盐酸二甲双胍比较,藤茶水提取剂量组对四氧嘧啶糖尿病小鼠血糖升高有抑制作用,具有明显的降糖效果。In the hypoglycemic experiment of rattan tea preparation of the present invention on experimental animal mice, the low, medium and high doses of rattan tea preparation of the present invention have significantly reduced serum glucose levels in mice compared with the blank control group, Statistically significant difference. Compared with the positive control drug metformin hydrochloride, the rattan tea water extract dosage group has an inhibitory effect on the increase of blood sugar in alloxan diabetic mice, and has an obvious hypoglycemic effect.

在降血压实验中,本发明的藤茶提取物浸膏及经各种有机溶剂分离所得浸膏,灌胃给药对刺激小鼠引起血压升高的耐受时间与空白对照组比较,均有显著延长,在统计学上有显著差异。与阳性药物对照普萘洛尔比较,耐受时间延长,疗效较阳性药物组普萘洛尔显著,具有明显的降压效果。通过藤茶降血脂、降血糖、降血压药效学实验,揭示本发明的藤茶制剂具有降血脂、降血糖、降血压的药理药效作用,且比阳性对照疗效好。In the blood pressure lowering experiment, the vine tea extract extract of the present invention and the extract extract obtained by separating various organic solvents, intragastric administration, compared with the blank control group have a significant effect on the tolerance time of stimulating the blood pressure in mice. Significantly prolonged, statistically significant difference. Compared with the positive drug control propranolol, the tolerance time is prolonged, the curative effect is more significant than that of the positive drug group propranolol, and it has obvious antihypertensive effect. Through the pharmacodynamic experiments of vine tea for lowering blood fat, blood sugar and blood pressure, it is revealed that the vine tea preparation of the present invention has pharmacological and pharmacological effects of lowering blood fat, blood sugar and blood pressure, and is better than the positive control.

本发明的有益效果:Beneficial effects of the present invention:

本发明制取得到的藤茶制剂含有19种人体必须的营养成份和微量元素,钙、铁、镁含量高,对心律失常、心肌缺血、高血压、冠心病、动脉粥样硬化等心血管疾病有较好的预防作用,对骨质疏松有很好的保健作用;富含的膳食纤维、胡萝卜素和维生素E,对癌症有较好的预防作用;锰含量高,极有利于长寿;对革兰氏阴性菌、流感甲型及乙型病毒均有抑制作用;本发明藤茶制剂:使用方便,患者可自行完成,服用量小,疗效迅速,携带方便,质量较稳定,其生产方法简单,有效成分提取率高,藤茶制剂成人使用剂量相当于3~6克中药材/次,每次2~3次,具备良好的降血糖、血脂、血压的功能。The vine tea preparation obtained by the present invention contains 19 kinds of essential nutrients and trace elements for the human body, high in calcium, iron, and magnesium, and is effective for arrhythmia, myocardial ischemia, hypertension, coronary heart disease, atherosclerosis, etc. It has a good preventive effect on diseases and a good health care effect on osteoporosis; rich in dietary fiber, carotene and vitamin E, has a good preventive effect on cancer; high manganese content is very beneficial to longevity; Gram-negative bacteria, influenza A and B viruses all have inhibitory effects; the rattan tea preparation of the present invention: easy to use, can be completed by patients, small dosage, rapid curative effect, easy to carry, relatively stable quality, and its production method is simple , The extraction rate of active ingredients is high. The dosage of vine tea preparation for adults is equivalent to 3-6 grams of Chinese herbal medicines per time, 2-3 times each time. It has a good function of lowering blood sugar, blood fat and blood pressure.

具体实施方式 Detailed ways

实施例1Example 1

藤茶嫩枝叶粉碎,过20目筛,加100℃水没过药材,提取二次,每次一小时,过滤,同时收集挥发油,合并滤液及挥发油,加入矫味剂,加水调节容量,制成口服液。Crush the twigs and leaves of rattan tea, pass through a 20-mesh sieve, add 100°C water to submerge the medicinal materials, extract twice, one hour each time, filter, collect volatile oil at the same time, combine the filtrate and volatile oil, add flavoring agents, add water to adjust the volume, and make it for oral administration liquid.

实施例2Example 2

藤茶嫩枝叶粉碎,过20目筛,加水100℃没过药材,提取三次,每次1小时,过滤,同时收集挥发油,合并滤液,滤液蒸干,得棕黑色浸膏,浸膏加入辅料,混合后再加入收集得到的挥发油,混匀,加入适量的本技术领域熟知的粘合剂,制粒干燥,加入润滑剂,压片机压成片剂,包糖衣,分装,即得藤茶片剂;可将制成的颗粒,加入适量的润滑剂装胶囊剂;也可颗粒分装制成颗粒剂。Crush the young branches and leaves of vine tea, pass through a 20-mesh sieve, add water at 100°C to submerge the medicinal materials, extract three times, each time for 1 hour, filter, collect volatile oil at the same time, combine the filtrate, and evaporate the filtrate to obtain a brown-black extract, add auxiliary materials to the extract, After mixing, add the collected volatile oil, mix evenly, add an appropriate amount of binders well known in the art, granulate and dry, add lubricant, press into tablets with a tablet machine, coat with sugar, and pack separately to obtain vine tea Tablets; the prepared granules can be filled into capsules by adding an appropriate amount of lubricant; the granules can also be subpackaged to make granules.

实施例3Example 3

藤茶嫩枝叶粉碎,过40目筛,经室温水超声提取三次,每次30分钟,过滤,合并滤液,滤液旋转蒸发仪蒸去溶液,得棕黑色浸膏。将浸膏喷雾干燥成粉末,过100-120目筛,装胶囊,分装,即得胶囊剂。The twigs and leaves of vine tea were crushed, passed through a 40-mesh sieve, ultrasonically extracted three times with room temperature water for 30 minutes each time, filtered, the filtrate was combined, and the filtrate was evaporated by a rotary evaporator to obtain a brown-black extract. The extract is spray-dried into powder, passed through a 100-120 mesh sieve, packed into capsules, and subpackaged to obtain capsules.

实施例4Example 4

藤茶嫩枝叶粉碎,不经过筛,经60℃水煎煮两次,每次一天,过滤,合并滤液,滤液加入氯仿萃取,静置,滤液分为两层,水层和氯仿层,去水层,得氯仿层。Crush the twigs and leaves of vine tea, without sieving, decocting in water at 60°C twice, each time for one day, filter, combine the filtrate, add chloroform to the filtrate for extraction, let stand, the filtrate is divided into two layers, the water layer and the chloroform layer, and remove the water layer to obtain a chloroform layer.

挥去氯仿,得墨绿色浸膏,浸膏再加入收集得到的挥发油,混匀,真空干燥或常压烘干(过80-100目筛)。加入适当浓度乙醇制成软材,制颗粒,干燥,加润滑油,混匀,压片机压片成片剂,包糖衣,分装,即得糖衣片剂。The chloroform is evaporated to obtain a dark green extract, which is then added to the collected volatile oil, mixed evenly, and dried in vacuum or under normal pressure (through a sieve of 80-100 mesh). Add appropriate concentration of ethanol to make a soft material, make granules, dry, add lubricating oil, mix well, compress into tablets with a tablet machine, coat sugar-coated, and pack separately to obtain sugar-coated tablets.

实施例5Example 5

同实施例4,提取溶液为乙醇,有机溶剂改为乙酸乙酯、石油醚等。Same as Example 4, the extraction solution is ethanol, and the organic solvent is changed to ethyl acetate, petroleum ether, etc.

实施例6Example 6

藤茶提取物制剂的降血脂药理学研究Pharmacological Study on Hypolipidemia of Rattan Tea Extract Preparation

1、实验动物:SD大鼠,雌雄各半,清洁级标准,共40只,随机分成4组,空白组、造模组、阳性对照组和供试品组,每组10只。SD大鼠连续给予高脂饲料饮食14天后,随机抽取每组30%的动物眼球后血管丛取血,检测总胆固醇(TC)、甘油三酯(TG)等血脂水平。结果,与空白对照组比较,高血脂模型成功率达到99%,证明造模型是成功的,剔除个别血脂水平偏低的动物后,进行降脂药物实验。1. Experimental animals: SD rats, half male and half male, clean standard, a total of 40 rats were randomly divided into 4 groups, blank group, model group, positive control group and test product group, 10 rats in each group. After the SD rats were continuously given high-fat diet for 14 days, 30% of the animals in each group were randomly selected to collect blood from the retroocular plexus, and blood lipid levels such as total cholesterol (TC) and triglyceride (TG) were detected. As a result, compared with the blank control group, the success rate of the hyperlipidemia model reached 99%, which proved that the model was successfully constructed. After excluding individual animals with low blood lipid levels, the lipid-lowering drug experiment was carried out.

2、样品来源与配制:2. Sample source and preparation:

(1)实施例1藤茶提取物水溶液A:藤茶提取浸膏水溶液A(相当于生药含量200mg/ml,给药剂量相当于生药2000mg/kg体重)。(1) Example 1 rattan tea extract aqueous solution A: rattan tea extract extract aqueous solution A (corresponding to crude drug content 200 mg/ml, dosage equivalent to crude drug 2000 mg/kg body weight).

(2)阳性对照组:取地奥心血康溶解于20毫升生理盐水中,制成悬液,浓度为30mg/ml,剂量为30mg/kg体重。(2) Positive control group: Di'ao Xinxuekang was dissolved in 20 ml of normal saline to make a suspension with a concentration of 30 mg/ml and a dose of 30 mg/kg body weight.

(3)生理盐水(氯化钠注射液),NaCl含量0.9%。(3) Physiological saline (sodium chloride injection), with a NaCl content of 0.9%.

3、实验方法:3. Experimental method:

高脂饲料饲养约第15天开始给药,实验各动物组分别经灌胃口服给药,灌胃量为相当于生药2g·kg-1,每天一次,连续给药共四周28天(末次给药后,禁食不禁饮8h)。全部动物经眼眶采血,取血清,检测血脂(给药后血脂)水平。结果见表1。The administration began on the 15th day of high-fat feed feeding, and each animal group in the experiment was administered orally by gavage. After taking the medicine, fasting and drinking for 8 hours). Blood was collected from all animals through the orbit, and serum was collected to detect the level of blood lipid (blood lipid after administration). The results are shown in Table 1.

4、实验结果4. Experimental results

经统计,藤茶提取物降血脂效果见下表1.According to statistics, the lipid-lowering effect of rattan tea extract is shown in the following table 1.

本发明的实施例1藤茶水提取物所得物,经过一个疗程的治疗后,受试药均在不同水平降低总胆固醇(TC)、甘油三酯(TG)水平。与高脂模型组和溶媒对照组比较,各受试药组均可降低总胆固醇(TC)水平和甘油三酯(TG)水平(P<0.05),在统计学上有显著差异。After a course of treatment of the vine tea water extract obtained in Example 1 of the present invention, the tested drugs all reduced the levels of total cholesterol (TC) and triglyceride (TG) at different levels. Compared with the high-fat model group and the vehicle control group, each test drug group can reduce the level of total cholesterol (TC) and triglyceride (TG) (P<0.05), and there is a statistically significant difference.

表1藤茶提取物降血脂药效研究 Table 1 Study on the efficacy of vine tea extracts in lowering blood lipids

Figure BSA00000495319800042
Figure BSA00000495319800042

*与空白组比较P<0.05,

Figure BSA00000495319800043
与造模组比较P<0.05,*P<0.05 compared with blank group,
Figure BSA00000495319800043
Compared with the modeling group, P<0.05,

实施例7Example 7

藤茶提取物制剂的降血糖药理学研究Hypoglycemic Pharmacology Study of Rattan Tea Extract Preparation

1、实验动物:NIH小鼠,雄性,体重18.0-23.1g,清洁级标准,共40只。随机分成4组,每组10只。设空白对照、阴性对照、阳性对照和藤茶水提取物组。1. Experimental animals: NIH mice, male, weighing 18.0-23.1g, clean standard, 40 in total. Randomly divided into 4 groups, 10 in each group. Set blank control, negative control, positive control and rattan tea water extract group.

2、样品来源与配置:2. Sample source and configuration:

(1)实施例1藤茶提取物水溶液A:藤茶提取浸膏水溶液A(相当于生药含量200mg/ml,给药剂量相当于生药2000mg/kg体重)。(1) Example 1 rattan tea extract aqueous solution A: rattan tea extract extract aqueous solution A (corresponding to crude drug content 200 mg/ml, dosage equivalent to crude drug 2000 mg/kg body weight).

(2)阳性对照组:盐酸二甲双胍(贵州天安药业有限责任公司产品)。(2) Positive control group: metformin hydrochloride (product of Guizhou Tianan Pharmaceutical Co., Ltd.).

(3)生理盐水(氯化钠注射液),NaCl含量0.9%。(3) Physiological saline (sodium chloride injection), with a NaCl content of 0.9%.

3、实验方法:四氧嘧啶至糖尿病模型3. Experimental method: alloxan to diabetes model

取正常小鼠尾静脉注射四氧嘧啶(72mg·kg-1),72h后预测血清葡萄糖水平,选用血糖值在16mmol·L-1以上者作研究。小鼠分为正常对照组,模型组,盐酸二甲双胍(150mg·kg-1)组,藤茶水提取剂量组(200mg·kg-1)组,每天灌胃给药1次,对照组和模型组给予等体积生理盐水,连续7d。于末次给药后1h,小鼠眼眶静脉丛取血测定血糖水平,结果见表2。结果表明,与模型组比较,藤茶水提取剂量组对四氧嘧啶糖尿病小鼠血糖升高有抑制作用,具有明显的降糖效果。Normal mice were injected with alloxan (72mg·kg -1 ) through the tail vein, and the serum glucose level was predicted 72 hours later. Those whose blood glucose level was above 16mmol·L -1 were selected for research. Mice were divided into normal control group, model group, metformin hydrochloride (150mg·kg -1 ) group, rattan tea water extract dose group (200mg·kg -1 ) group, intragastric administration once a day, control group and model group were given Equal volume of normal saline for 7 days. One hour after the last administration, blood was taken from the orbital venous plexus of the mice to measure the blood glucose level, and the results are shown in Table 2. The results showed that, compared with the model group, the rattan tea water extract dose group had an inhibitory effect on the increase of blood sugar in alloxan diabetic mice, and had an obvious hypoglycemic effect.

4、实验结果:4. Experimental results:

经统计,各剂量组半数咳嗽时间及止咳效果见下表2。According to statistics, the half cough time and antitussive effect of each dose group are shown in Table 2 below.

表2藤茶水提浸膏的止咳效果Table 2 The cough-relieving effect of rattan tea water extract

Figure BSA00000495319800044
Figure BSA00000495319800044

Figure BSA00000495319800051
Figure BSA00000495319800051

*与空白组比较P<0.01*Compared with the blank group, P<0.01

实施例8Example 8

藤茶提取物制剂的降血压药理学研究Antihypertensive Pharmacology Study of Rattan Tea Extract Preparation

1、实验动物:Wistar大鼠,雄性,体质量(250±26.3)g。1. Experimental animals: Wistar rats, male, body weight (250±26.3) g.

2、样品来源与配制:2. Sample source and preparation:

(1)实施例1藤茶提取物水溶液A:藤茶提取浸膏水溶液A(相当于生药含量200mg/ml,给药剂量相当于生药2000mg/kg体重)。(1) Example 1 rattan tea extract aqueous solution A: rattan tea extract extract aqueous solution A (corresponding to crude drug content 200 mg/ml, dosage equivalent to crude drug 2000 mg/kg body weight).

(2)阳性对照组:普萘洛尔(山西云鹏制药有限公司)。(2) Positive control group: propranolol (Shanxi Yunpeng Pharmaceutical Co., Ltd.).

(3)生理盐水(氯化钠注射液),NaCl含量0.9%。(3) Physiological saline (sodium chloride injection), with a NaCl content of 0.9%.

3、实验方法:胸动脉离体血管张力研究法3. Experimental method: thoracic artery isolated vascular tension research method

3.1、胸主动脉血管环的制备与稳定3.1. Preparation and stabilization of thoracic aortic ring

大鼠断头处死,开胸迅速取出胸主动脉,置于预先用混合气体(95%O2和5%CO2)饱和的4℃的K-H液中,冲洗至无血迹,小心地去除外周的脂肪组织和结缔组织,并剪成2~3mm长的血管环,将血管环置于盛有10ml的K-H液(37℃恒温,并持续通入95%O2和5%CO2的混和气体,pH=7.4)的恒温套瓶中,每一根血管环用两个三角型挂钩贯穿血管环管腔,一端固定,另一端连接于张力传感器,张力变化由BL-420E生物机能实验系统采集并记录。血管环加静息张力2g左右,稳定90min,期间每15min用预温至37℃的K-H液更换液体。待血管环完全稳定后,即可进行正式实验。Rats were decapitated, and the thoracic aorta was quickly taken out by opening the chest, placed in KH solution at 4°C saturated with mixed gas (95% O 2 and 5% CO 2 ), washed until there was no blood, and the peripheral blood was carefully removed. Adipose tissue and connective tissue were cut into 2-3mm long vascular rings, and the vascular rings were placed in 10ml of KH solution (at a constant temperature of 37°C, and a mixed gas of 95% O 2 and 5% CO 2 was introduced continuously, In the constant temperature jacket bottle with pH=7.4), each blood vessel ring is penetrated by two triangular hooks through the lumen of the blood vessel ring, one end is fixed, and the other end is connected to the tension sensor, and the tension change is collected and recorded by the BL-420E biological function experiment system . The vascular ring was added with a resting tension of about 2g, and it was stable for 90 minutes. During this period, the liquid was replaced with KH solution pre-warmed to 37°C every 15 minutes. After the vascular ring is completely stable, the formal experiment can be carried out.

3.2、藤茶提取物对氯化钾预收缩的血管环张力的影响3.2. The effect of rattan tea extract on the tension of vascular rings pre-contracted by potassium chloride

待血管环稳定后,用60mmol/L的KCl重复刺激3次,诱发血管的最大收缩幅度,连续3次同样的刺激所引起的收缩幅度差别<10%时,以此做为100%收缩张力。按浓度梯度分别加入组药物。After the vascular ring was stabilized, it was repeatedly stimulated with 60 mmol/L KCl 3 times to induce the maximum contraction range of the blood vessel. When the contraction range difference caused by 3 consecutive same stimulations was less than 10%, it was regarded as 100% contraction tension. Drugs were added to each group according to the concentration gradient.

Figure BSA00000495319800052
Figure BSA00000495319800052

4、实验结果:4. Experimental results:

经统计,藤茶提取物降血压的效果见下表3.According to statistics, the blood pressure-lowering effect of vine tea extract is shown in Table 3 below.

本发明的藤茶提取物浸膏及经各种有机溶剂分离所得浸膏,灌胃给药对刺激小鼠引起血压升高的耐受时间与空白对照组比较,均有显著延长,在统计学上有显著差异。与阳性药物对照普萘洛尔比较,耐受时间延长,疗效较阳性药物组普萘洛尔显著。Compared with the blank control group, the rattan tea extract extract of the present invention and the extracted extract obtained by separating various organic solvents, administered through stomach, have a significant prolongation compared with the blank control group. There are significant differences. Compared with the positive drug control propranolol, the tolerance time was prolonged, and the curative effect was more significant than that of the positive drug group propranolol.

表3.藤茶提取物降血压效果Table 3. Antihypertensive effect of vine tea extract

Figure BSA00000495319800061
Figure BSA00000495319800061

本发明的藤茶制剂对实验动物的实验表明,本发明的藤茶制剂灌胃给药对大鼠血脂、血糖及血压与空白对照组比较,均有显著降低,在统计学上有显著差异。在降血脂试验中,与阳性药物地奥心血康对照比较,实施例组对大鼠血脂有显著降低,在统计学上有显著差异;实施例6降血脂效果优于阳性对照物,经试验,本发明的其他实施例显示与实施例6具备相似的效果。The experiment of rattan tea preparation of the present invention on experimental animals shows that compared with the blank control group, rats' blood lipid, blood sugar and blood pressure can be significantly reduced by gavage administration of the rattan tea preparation of the present invention, and there is a statistically significant difference. In the blood lipid-lowering test, compared with the positive drug Di'ao Xinxuekang contrast, the embodiment group has significantly reduced the blood fat of rats, and there is a statistically significant difference; the effect of reducing blood fat in Example 6 is better than that of the positive control. After testing, the drug of the present invention Other embodiments show similar effects to embodiment 6.

根据上述说明书的揭示和教导,本发明所属领域的技术人员还可以对上述实施方式进行变更和修改。因此,本发明并不局限于上面揭示和描述的具体实施方式,对本发明的一些修改和变更也应当落入本发明的权利要求的保护范围内。此外,尽管本说明书中使用了一些特定的术语,但这些术语只是为了方便说明,并不对本发明构成任何限制。According to the disclosure and teaching of the above-mentioned specification, those skilled in the art to which the present invention belongs can also make changes and modifications to the above-mentioned embodiment. Therefore, the present invention is not limited to the specific embodiments disclosed and described above, and some modifications and changes to the present invention should also fall within the protection scope of the claims of the present invention. In addition, although some specific terms are used in this specification, these terms are only for convenience of description and do not constitute any limitation to the present invention.

Claims (9)

1. vine tea preparation of hypoglycemic a, blood fat, blood pressure and preparation method thereof; It is characterized in that: the production method of vine tea preparation once may further comprise the steps: the vine tea browse is pulverized, and water is carried or alcohol extracting one to three time; Aqueous extract filters; Merging filtrate is condensed into medicinal extract, processes oral formulations by conventional method.
2. vine tea preparation of a kind of hypoglycemic, blood fat according to claim 1, blood pressure and preparation method thereof; It is characterized in that: vine tea preparation, its raw material are the browses of vine tea, with the water extract of vine tea or alcohol extract as active ingredient; Process pharmaceutical composition, formulation is a peroral dosage form.
3. pharmaceutical composition according to claim 2 is characterized in that: said composition is to add tablet, capsule, granule, oral liquid or the aerosol etc. that acceptable auxiliary is processed on the pharmacy with described active ingredient.
4. pharmaceutical composition according to claim 2 is characterized in that: said vine tea is meant it and just adopts browse or its browse through processing.
5. vine tea preparation of a kind of hypoglycemic, blood fat according to claim 1, blood pressure and preparation method thereof, it is characterized in that: said vine tea preparation raw material is the single of vine tea, or its composition.
6. vine tea preparation of a kind of hypoglycemic, blood fat according to claim 1, blood pressure and preparation method thereof is characterized in that: behind the merging filtrate, add organic solvent extraction, reclaim organic solvent, get organic solvent layer, be condensed into medicinal extract.
7. vine tea preparation according to claim 6 is characterized in that: after being condensed into medicinal extract, add flavouring, add the water pondage, process oral liquid.
8. vine tea preparation according to claim 6 is characterized in that: after being condensed into medicinal extract, add auxiliary material, mix, add the volatile oil of having collected, granulate, add the conventional auxiliary material compressing tablet of tablet, process tablet.
9. vine tea preparation of a kind of hypoglycemic, blood fat according to claim 1, blood pressure and preparation method thereof, it is characterized in that: this oral formulations can be health products or medicine.
CN2011101234671A 2011-05-13 2011-05-13 Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method Pending CN102771593A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011101234671A CN102771593A (en) 2011-05-13 2011-05-13 Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011101234671A CN102771593A (en) 2011-05-13 2011-05-13 Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method

Publications (1)

Publication Number Publication Date
CN102771593A true CN102771593A (en) 2012-11-14

Family

ID=47116908

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011101234671A Pending CN102771593A (en) 2011-05-13 2011-05-13 Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method

Country Status (1)

Country Link
CN (1) CN102771593A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106690317A (en) * 2016-11-11 2017-05-24 贵州黔贵天赐大健康集团有限公司 Radix salviae miltiorrhizae composition and preparation method thereof
CN107397843A (en) * 2016-05-19 2017-11-28 苏州凯祥生物科技有限公司 Application of the Ampelopsis grossedentata extrat in farnesoid X receptor activator is prepared
CN108771718A (en) * 2018-08-09 2018-11-09 简能茶业开发有限公司 For hypoglycemic mixture containing plant component and the preparation method and application thereof
CN108904643A (en) * 2018-08-09 2018-11-30 简能茶业开发有限公司 Mixture containing plant component and the preparation method and application thereof for reducing blood lipid
CN110856715A (en) * 2018-08-24 2020-03-03 株式会社芳珂 Composition, tablet and capsule containing vine tea extract
CN113498819A (en) * 2021-08-19 2021-10-15 武汉禾本泰医药科技有限公司 Lipid-lowering tea
CN114177236A (en) * 2021-12-08 2022-03-15 怀化学院 Preparation method and application of ampelopsis grossedentata extract particles
CN115745937A (en) * 2022-09-28 2023-03-07 湖南中医药大学 New compound rubus parvifolius tea extract A and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63279A (en) * 1986-06-20 1988-01-05 Masahisa Murakami Preparation of rapidly soluble ampelopsis tea
JPH063279A (en) * 1992-06-17 1994-01-11 Nagase & Co Ltd Method and device for inspecting hard disc or wafer
CN1104454A (en) * 1994-09-16 1995-07-05 吴林咀 Cane tea
CN1706426A (en) * 2004-06-04 2005-12-14 澳美制药厂有限公司 Application of snake grape plants and its extracts in the preparation of medicines and health products
CN1711918A (en) * 2004-06-25 2005-12-28 广东省农业科学院蚕业与农产品加工研究所 A kind of production method of rattan tea stoste
CN101642179A (en) * 2009-09-08 2010-02-10 项金秀 Tea beverage with functions of lowering pressure, lowering sugar and lowering fat

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63279A (en) * 1986-06-20 1988-01-05 Masahisa Murakami Preparation of rapidly soluble ampelopsis tea
JPH063279A (en) * 1992-06-17 1994-01-11 Nagase & Co Ltd Method and device for inspecting hard disc or wafer
CN1104454A (en) * 1994-09-16 1995-07-05 吴林咀 Cane tea
CN1706426A (en) * 2004-06-04 2005-12-14 澳美制药厂有限公司 Application of snake grape plants and its extracts in the preparation of medicines and health products
CN1711918A (en) * 2004-06-25 2005-12-28 广东省农业科学院蚕业与农产品加工研究所 A kind of production method of rattan tea stoste
CN101642179A (en) * 2009-09-08 2010-02-10 项金秀 Tea beverage with functions of lowering pressure, lowering sugar and lowering fat

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107397843A (en) * 2016-05-19 2017-11-28 苏州凯祥生物科技有限公司 Application of the Ampelopsis grossedentata extrat in farnesoid X receptor activator is prepared
CN106690317A (en) * 2016-11-11 2017-05-24 贵州黔贵天赐大健康集团有限公司 Radix salviae miltiorrhizae composition and preparation method thereof
CN108771718A (en) * 2018-08-09 2018-11-09 简能茶业开发有限公司 For hypoglycemic mixture containing plant component and the preparation method and application thereof
CN108904643A (en) * 2018-08-09 2018-11-30 简能茶业开发有限公司 Mixture containing plant component and the preparation method and application thereof for reducing blood lipid
CN110856715A (en) * 2018-08-24 2020-03-03 株式会社芳珂 Composition, tablet and capsule containing vine tea extract
CN110856715B (en) * 2018-08-24 2024-09-03 株式会社芳珂 Composition, tablet and capsule containing vine tea extract
CN113498819A (en) * 2021-08-19 2021-10-15 武汉禾本泰医药科技有限公司 Lipid-lowering tea
CN114177236A (en) * 2021-12-08 2022-03-15 怀化学院 Preparation method and application of ampelopsis grossedentata extract particles
CN115745937A (en) * 2022-09-28 2023-03-07 湖南中医药大学 New compound rubus parvifolius tea extract A and preparation method thereof
CN115745937B (en) * 2022-09-28 2024-05-31 湖南中医药大学 A new compound tea berry element A and its preparation method

Similar Documents

Publication Publication Date Title
CN102771593A (en) Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method
CN102772586A (en) Preparation with hangover alleviating and liver protection functions and preparation method thereof
CN104431064B (en) A kind of blood-sugar reducing tea and preparation method thereof
US10111451B2 (en) Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor
JPS60214741A (en) Hypoglycemic agent
JP6355248B2 (en) Sympathetic nerve activator
CN102127043A (en) Method for extracting and separating pueraria flavonid and pueraria polysaccharide
CN109602759B (en) Application of podocarpus macrophyllus polysaccharide
CN103564495B (en) Propolis and cordycepic hypha powder composition, as well as preparation and application thereof
CN1616381A (en) Process for preparing Erigeron breviscapus active component
CN106109488A (en) The application in preparing the food or medicine with blood fat reducing function of a kind of Quinoa polysaccharide
CN102872195B (en) A kind of preparation method and application thereof of Chinese cassia tree total polyphenols extract
CN104887835A (en) Healthcare product prepared through natural plants
CN104666643A (en) Compound plains coreopsis product, as well as preparation method and application thereof
CN101254217A (en) A preparation method of the extract of the renewable part of the yew tree and the application of the extract in the preparation of oral anticancer drugs
CN102370677A (en) Three-flavor sandalwood preparation and preparation method thereof
CN101890152A (en) Application of Chinese yam glycoprotein in preparation of anti-hypoxia and anti-fatigue medicines
JP2004352626A (en) Anti-cholesterol agent containing plant-derived components
CN104435072B (en) A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid
CN102302545A (en) Dai medicine extract with blood-sugar reducing activity, preparation method, composition and application
CN110123859B (en) Chrysanthemum leaf extract for preventing and treating liver injury and its application
KR101379368B1 (en) Composition for treating alcohol intoxication containing fructus xanthii extracts and method of preparing the extracts
CN101502536B (en) Cedar total flavone and preparation method and medical application thereof
CN100448458C (en) Composition of balsam pear wound juice and its preparation method and application
JP5969308B2 (en) Nitric oxide secretion promoter or secretion inducer of vascular endothelial cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121114